CYTOKINETICS, INCORPORATED Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
CYTOKINETICS, INCORPORATED (CYTK) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $47.04 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-02-26
- CYTOKINETICS, INCORPORATED share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2015-03-31 was $7.75, a 25.00% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2014-03-31 was $6.20, a 339.72% increase year-over-year.
- CYTOKINETICS, INCORPORATED share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2013-03-31 was $1.41.
- CYTOKINETICS, INCORPORATED share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $47.04, a 15.04% increase from fiscal 2024.
- CYTOKINETICS, INCORPORATED share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $40.89, a 16.80% increase from fiscal 2023.
- CYTOKINETICS, INCORPORATED share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $35.01, a 20.97% increase from fiscal 2022.
- CYTOKINETICS, INCORPORATED share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $28.94, a 98.76% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-12-31 | $47.04 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $40.89 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $35.01 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $28.94 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $14.56 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $16.06 10-K · filed 2023-03-01 | |||
| 2019-12-31 | $10.44 10-K · filed 2021-02-26 | |||
| 2018-12-31 | $11.06 10-K · filed 2019-03-07 | |||
| 2015-09-30 | $7.58 10-Q · filed 2015-11-05 | |||
| 2015-06-30 | $7.56 10-Q · filed 2015-08-05 | |||
| 2015-03-31 | $7.75 10-Q · filed 2015-05-04 | |||
| 2014-09-30 | $7.31 10-Q · filed 2014-11-06 | |||
| 2014-06-30 | $6.54 10-Q · filed 2014-08-07 | |||
| 2014-03-31 | $6.20 10-Q · filed 2014-05-07 | |||
| 2013-09-30 | $4.88 10-Q · filed 2013-11-06 | |||
| 2013-06-30 | $4.88 10-Q · filed 2013-08-07 | |||
| 2013-03-31 | $1.41 10-Q · filed 2013-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |